Revatio (sildenafil): Drug Safety Communication - FDA clarifies Warning About Pediatric Use for Pulmonary Arterial Hypertension

Health care professionals must consider whether the benefits of treatment with the drug are likely to outweigh its potential risks for each patient.

 
comments powered by Disqus